Clinical safety evaluation of Endeavor stent in octogenerians. - E-OCTO Registry

Cardiovascular center, Shinkawabashi hospital0 sites200 target enrollmentSeptember 1, 2010

Overview

No summary available.

Registry

who.int

Start Date

September 1, 2010

End Date

TBD

Last Updated

2 years ago

Study Type

Observational

Sex

All

Sponsor

Cardiovascular center, Shinkawabashi hospital

•1\)Limited Life expectancy within 12months. 2\)Inability to comply with the required IFU antiplatelet regimen. 3\)Ejection Fraction\<30%. 4\)Unprotected LMT disease. 5\)Chronic Total Occulution. 6\)The lesions in all native coronary arteries, LCX/LAD/RCA should be amenable to PCI. 7\)Severe valvular disease. 8\)Renal Failure. 9\)Taking Warfarin Potassium. 10\)Planed PCI of any vessel within 30 days post\-index procedure and/or planed PCI of the target vessel(s) within 12 months post\-procedure. 11\)Known hypersensitivity or contraindication to aspirin, heparin, clopidogrel and ticlopidine, cobalt, nickel, chromium, molybdenum, polymer coating (e.g.PC polymer) or a sensitivity to contrast media, which cannot be adequately pre\-medicated. 12\)Acute myocardial infaction with cardogenic shock. 13\)Previous stenting in the target vessel(s). 14\)Prior to enrollment in this study, if a surgical or any procedure is anticipated that would require early discontinuation of 3\-month antiplatelet therapy. 15\)Patient is not an acceptable candidate for PCI at a physician's discretion.